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Abstract
Background: Circulating tumour cells (CTCs) have been found to be a prognostic marker for reduced disease free
survival, breast cancer–specific survival, and overall survival before the start of systemic treatment.
Methods: A total of 200 patients’ sera were included in this study, 100 patients being CTC positive and 100
patients being CTC negative. Matching criteria were histo-pathological grading, lymph node metastasis, hormone
receptor status, TNM classification and survived breast cancer patients vs. deceased tumor associated patients. A
multi cytokine/chemokine array was used to screen the sera for the angiogenic markers.
Results: Statistical significant correlation was exposed for sFlt1 values in regard to the CTC-Status. CTC negative
patients displayed increased sFlt1 expression opposed to CTC positive breast cancer patients. Furthermore,
significant enhanced PIGF values were also disclosed in CTC negative patients compared to patients being CTC
positive. Analyzing the living patient collective we found significant differences in sFlt1 and PlGF values in regard to
CTC negative and CTC positive patients.
Conclusion: Both vascular markers showed enhanced expression in the CTC negative patient collective. To
continue, the collective graded G2 showed significantly enhanced sFlt1 expressions amongst patients with no CTCs.
Moreover, the patient collective with no lymph node metastasis and CTC negativity indicated statistically significant
increased sFlt1 values. A functional interaction of sFlt1 and PlGF was found, suggesting that their overexpression in
tumour cells inhibits CTCs entering the peripheral blood. Furthermore, in regard to CTC negativity, sFlt1 and PlGF
values may potentially serve as predictive markers.
Trial registration: The TRN of this study is NCT02181101 and the date of registration was the 4th of June 2014. The
study was retrospectively registered.
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Background
Worldwide, breast cancer is the most common tumour
diagnosed in women with an estimated 1.7 million new
breast cancer cases and 522,000 breast cancer deaths in
2012 [1]. Whereby, the survival of breast cancer patients
is intensely associated with prognostic factors such as
tumour size, hormone-receptor-profile and presence of
metastases [2]. New approaches have also established a
correlation between poor prognosis and the detection of
Circulating tumour cells (CTCs) before the start of sys-
temic treatment [3]. CTCs in the peripheral blood can be
used as a prognostic marker for reduced disease free-,
breast cancer specific-, and overall- survival before the
start of systemic treatment [3–7]. The detection of CTCs
shortly after commence of therapy even provide comple-
mentary information concerning treatment response [6].
The SUCCESS study was one of the first trials to indicate
the strong prognostic importance, associated with a less
favourable outcome, of CTCs in early breast cancer before
commencing systemic adjuvant treatment and after adju-
vant chemotherapy in a large patient cohort [8].
It is increasingly evident that not only the breast can-
cer cells itself, but also the microenvironment of the
tumour plays a significant role in terms of tumour pro-
gression, metastasis formation and treatment response
[9]. To continue, tumour angiogenesis acts as a crucial
factor in the microenvironment in the development and
progression of breast cancer. In correspondence to the
arising significance of CTC involvement in cancer therapy,
the aim of this study was the evaluation of tumour-
angiogenesis markers in association to CTC involvement.
Furthermore, vascular markers could act as indicators for
the absence or presence of CTCs, as the determination of
CTCs is a time intense and expensive technique.
Neo-angiogenesis, the process of new blood capillary for-
mation from pre-existing vessels, acts as a fundamental part
in both embryonic and postnatal development, in the re-
modelling of various organ structures, and in particular in
tumour growth [10]. Its precarious involvement with
tumour evolution and penetration has already become a
promising focus in cancer therapy [2]. It is implied that
angiogenesis in tumours is part of a multistep progression
including the signalling between breast cancer cells and
several cell types within the tumours microenvironment [2,
10]. A range of pro-angiogenic cytokines, which succumb
an overexpression of factors by the tumour, induces Angio-
genesis [11]. One of the best described is the vascular endo-
thelial growth factor (VEGF). This process of neo-
vascularisation is also referred to as the “angiogenic switch”
[2, 12]. This describes the transition of tumour cells, where
the balance between pro- and anti-angiogenic factors lean
towards pro-angiogenic markers, designating a progression
to an expanding vascularized tumour and eventually to ma-
lignant behaviour [11–13]. Consequently our intention was
to analyse the distribution of angiogenic markers: sFlt1,
PlGF, VEGF, VEGF-C and VEGF-D and disclose the differ-
ences of their expression in breast cancer patients of the
SUCCESS study group in terms of CTC involvement,
histo-pathological grading, lymph node metastasis, hor-
mone receptor status, TNM classification and survived
breast cancer patients vs. deceased tumour associated pa-
tients. A Sandwich immunoassay ELISA and anti-species
Multi-Array 96 well plates were used to screen the blood
serum samples that enabled us to screen for all mentioned
vascular markers in just one well at the same time.
The cytokines belonging to the vascular endothelial
growth factor (VEGF) family and its important involve-
ment in angiogenesis have been subject of major interest.
The VEGF family includes six related gene members;
VEGF, VEGF-B, VEGF-C, VEGF-D, VEGF-F and placental
growth factor (PIGF) that are regulators of angiogenesis
or lymphangiogenesis or of both processes [2, 11, 14]. To
continue, the markers have been described to bind with
diverse affinity to one of the three tyrosine kinase recep-
tors known as vascular endothelial growth factor receptor
VEGFR-1 (sFlt1), VEGFR-2 and VEGFR-3 [15–17], initiat-
ing a signalling cascade promoting survival, growth and
migration of tumour cells [2, 18]. Increased levels of
VEGF in tumour patients have been described as a well-
established indicator of poor prognosis [19]. PIGF and
sFlt1 on the other hand have been known to play a major
role in preeclampsia, and even associated with a lower
breast cancer risk later in life of those patients [20, 21].
In conclusion, the assessment of vascular tumour angio-
genesis markers in relationship to CTC involvement and
the expression of angiogenesis markers in terms of histo-
pathological grading, lymph node involvement, hormone
receptor status, TNM classification and survived breast
cancer patients vs. deceased tumour associated patients,
could found an advantage in regard to assessing the
discrete risk of patients at the time of primary diagnosis.
The assessment of the angiogenesis factors in patients
with different phenotype breast cancer, could furthermore
allow a profounder understanding of how angiogenesis-
related genes may influence breast carcinogenesis, thus
allowing an increased enhanced individualized treatment.
Methods
Study design and ethical board permission
Eligible patients were defined as women with breast
cancer (stages pT1–T4, pN0–N3, M0) who accepted to
participate in the phase I SUCCESS study (www.su
ccess-studie.de). SUCCESS was a prospective, random-
ized adjuvant study comparing three cycles of fluorouracil-
epirubicin-cyclo-phosphamide (FEC; 500/100/500 mg/m2)
followed by 3 cycles of docetaxel (100 mg/m2) every
3 weeks vs. three cycles of FEC followed by 3 cycles of gem-
citabine (1000 mg/m2 d1,8)-docetaxel (75 mg/m2) each
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3 weeks. After the completion of chemotherapy, the pa-
tients were furthermore randomized to receive either 2 or
5 years of zoledronate. Hormone receptor–positive women
moreover received suitable endocrine treatment. The re-
search questions related to CTC analysis, the blood sam-
pling time points, and the methodology were prospectively
designed, and the prognostic value of the CTCs was de-
scribed as a scientific objective of the study protocol. The
study was permitted by 37 German ethical boards (lead eth-
ical board: LMU, Munich) and conducted in agreement
with the Declaration of Helsinki.
Blood samples for CTC enumeration were collected
from 2090 consecutive patients after complete resection
of the primary tumour and before adjuvant chemother-
apy after written informed consent was acquired. Never-
theless, sixty-four patients were disqualified because of
test failure or a time intermission of more than 96 h
between the blood collection and sample preparation. A
follow-up evaluation after chemotherapy and before the
beginning of endocrine or bisphosphonate treatment
was available for a subgroup of 1492 patients (see home
page: http://www.success-studie.de).
Patients
In this study 200 Patients of the SUCCESS study were
incorporated and assigned into two groups: 100 Pa-
tients were CTC positive (Group 1. CTC Positive) and
the other 100 Patients were CTC negative (Group 2.
CTC Negative). These two groups were then framed
and investigated correspondingly. Patients from re-
spectively groups were then matched into pairs of two
rendering to histo-pathological grading, lymph node
involvement, hormone receptor type, TNM classifica-
tion and survived patients vs. deceased patients breast
cancer associated. The 200 patient samples that were
investigated contained 160 patients that were still alive
at last observation after end of therapy and 40 patients
that had deceased during therapy tumour associated.
Furthermore, the groups considered contained 98 pa-
tients graded G2 and 102 patients graded G3. Matching
criteria of the 200 breast cancer patients did not allow
patients graded G1. Tumour stage of the anamnestic diag-
nosis was categorised according to the TNM-classification,
which was conducted correspondingly to the WHO Sys-
tem [22]. The matching of patients was executed accord-
ing to the criteria at the time of primary diagnosis. The
histo-pathological grading was classified conferring to the
Bloom and Richardson system classification [23].
Collection of blood samples and Detection of CTCs
Method was conducted as defined by the SUCCESS
Study group [8]. CTCs were examined using the Cell-
Search System (Veridex, Raritan, NJ). Peripheral blood
was drawn into three CellSave tubes (3x10 mL – Serum
Vacutainer from BD Ref. Nr. 367896), sent at room
temperature to the central laboratory at the University of
Munich, and inspected within 96 h of collection. Conse-
quently, the patient sera was frozen at −80 °C and seasoned
in Nitrogen for long-term storage.
The patient blood samples were then centrifuged for
10 min at 800 × g. The plasma was removed, and a dilution
buffer was added. This arrangement was overlaid on 6 mL
of Histopaque (Sigma, Steinheim, Germany) and centri-
fuged for 10 min at 400 × g. Subsequently, 7.5 mL of this
sample enclosing the buffy coat was treated on the Cell-
Tracks AutoPrep system using the CellSearch Epithelial Cell
Kit (Veridex). After immuno-magnetic enrichment with an
anti-Epcam antibody, the cells were marked with fluores-
cent anticytokeratin (CK8, 18, 19–phycoerythrin) and anti-
CD45 antibodies (CD45–allophycocyan), and 4,6-diami
dino-2-phenylindoledihy-drochloride was used to classify
the intact cells.
The identification, documentation and enumeration of
CTCs were achieved using the CellTracks Analyzer II. CTCs
were stated as nucleated cells lacking CD45 and expressing
cytokeratin. Two independent investigators assessed all posi-
tive samples. The samples with a minimum of one CTC per
30 mL of blood were considered as CTC positive.
Measurement of cytokines
ELISA was performed with recently developed multi cyto-
kine/chemokine arrays (Meso Scale Discovery®, Rockville,
USA) to screen the blood serum samples for the vascular
markers sFlt1, PIGF, VEGF, VEGF-C and VEGF-D. The
immunoassays were commercially available. We used anti-
species MULTI-ARRAY 96-well plates for the develop-
ment of a sandwich immunoassay. Each assay in the panel
was verified individually for the Specificity by running
single calibrator with single detection antibodies. Non-
specific binding levels were less than 0.5 % for all assays.
The 10 spot MULTI-SPOT plates were pre-coated with
capture antibodies on independent and well defined spots
that allowed us to immobilize a primary capture antibody
against our protein of interest - specific for one of each
vascular marker. Standards and samples were added to the
appropriate wells. A standard curve was furthermore run
with each assay. We firstly added the blood serum,
calibrator and control. After that we incubated at room
temperature with shaking for 2 h. After eliminating excess
samples from the well with wash buffer, we added a solu-
tion containing the detection (anti-target) antibody conju-
gated with electrochemiluminescent labels over the course
of two incubation periods. During incubation time, where
time slots differed in each test, the target present in the
sample bound to the capture antibody immobilized on the
working electrode surface by the anti-species antibody. Re-
cruitment of the labelled detection antibody by the bound
target completed the sandwich. After a second shaking
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incubation period (time differed for each test) wash buffer
was used to eliminate the entire unbound enzymes and a
MSD Read Buffer was added to produce the suitable
chemical environment for electrochemiluminescence. We
then loaded the plate into an MSD instrument (MESO
QuickPlex SQ 120) for examination where voltage applied
to the plate electrodes caused the captured labels to emit
light. The instrument calculated the intensity of the emit-
ted light to present a quantitative measure of the amount
of the protein of interest that was present in the sample
[24, 25] (see homepage: www.mesoscale.com).
Statistical analysis
Statistical analysis was implemented using SPSS 22.0
(SPSS Inc., IBM, Chicago, IL). The outcomes collected
were recorded and inserted into the SPSS database in
the implied manner. We evaluated the relationship be-
tween each vascular marker: sFlt1, PIGF, VEGF, VEGF-C
and VEGF-D and each matching criteria (1. CTC-
Positive vs. CTC-Negative, 2. Patient survived vs. Patient
deceased, 3. Grading G2 vs. Grading G3, 4. Lymph node
involvement vs. No lymph node involvement, 5. Triple
positive vs. Triple negative 6. Progesterone receptor-
positive vs. Progesterone receptor-negative, 7. Oestrogen
receptor-positive vs. Oestrogen receptor-negative, 8. Her
2/neu receptor-positive vs. Her 2/neu receptor-negative)
in the total patient collective and also regarding each
matching criteria alone, by the use of the non-parametric
Spearman correlation coefficient. Each parameter to be
considered needed to have a p value <0.50. Statistical sig-
nificant results within the Spearman correlation coefficient
were then additionally assessed with the non-parametric
Mann-Whitney-U-test. Moreover, variables were scruti-
nized by the use of Box-Plot analysis. All statistical tests
were considered significant at p < 0.05.
Results
CTC positive vs. CTC negative
In the total patient collective, statistical significant differ-
ences were shown for sFlt1 values in regard to the CTC-
Status. Box-plot analysis revealed that CTC negative
patients exposed increased sFlt1 expression opposed to
the CTC positive breast cancer patients that showed
decreased sFlt1 values. The spearman correlation coeffi-
cient assessed the p-value of 0.034, additionally sup-
ported by the Mann-Whitney-U-Test p = 0.034, proving
a significant correlation between CTC-status and sFlt1.
In addition, ROC analysis was performed, exposing an
AUC value of 0.413 (see Fig. 1a).
Furthermore, a statistical significant correlation was
found for PIGF values concerning the CTC-status. Box-
plot analysis identified significant enhanced PIGF values
in CTC negative patients compared to patients being CTC
positive. The spearman correlation coefficient assessed the
p-value of 0.043 which was moreover supported by the
Mann-Whitney-U-Test p = 0.043. ROC analysis imple-
mented an AUC value of 0.417. (see Fig. 1b).
Nevertheless, the statistical analysis confirmed no sig-
nificant correlation in terms of the CTC-Status regard-
ing the vascular markers VEGF, VEGF-C, VEGF-D.
Patient survived vs. patient deceased
Analysing the patient collective who were still alive, and
did not decease breast cancer associated, these showed
statistically significant differences between CTC negative
and CTC positive patients in terms of the vascular
marker sFlt1. The box-plot analysis revealed that the
survived patients collective who were CTC negative dis-
play higher levels of sFlt1 compared to the reduced
values of sFlt1 in the survived patients with the presence
of CTCs. The spearman correlation coefficient assessed
the p-value of 0.030 which was additionally supported by
the Mann-Whitney-U-Test p = 0.030. To continue, ROC
analysis was performed, displaying an AUC value of
0.401 (see Fig. 2a).
Moreover, a statistical significant correlation was also
proven for survived breast cancer patients being either
CTC negative or CTC positive in respect to the vascular
marker PIGF. The box-plot analysis disclosed that the
survived patients collective who were CTC negative
demonstrate increased PIGF expression in comparison
to the decreased PIGF values in the survived patients
being CTC positive. The spearman correlation coeffi-
cient evaluated the p-value of 0.025 which was further-
more reinforced by the Mann-Whitney-U-Test p = 0.026.
ROC analysis was executed, revealing an AUC value of
0.398 (see Fig. 2b).
However, the statistical analysis verified no significant
correlation in the survived patient collective regarding
the vascular markers VEGF, VEGF-C, VEGF-D. To con-
clude, statistical analysis also demonstrated no signifi-
cant differences concerning the deceased patients who
had died breast cancer associated, with and without the
presence of CTCs, in respect to the vascular markers
sFlt1, PIGF, VEGF, VEGF-C and VEGF-D.
Lymph node involvement vs. no lymph node involvement
The patient collective with no lymph node metastasis in-
dicated statistically significant differences between CTC
negative and CTC positive breast cancer patients in re-
gard to the vascular marker sFlt1. Box-plot analysis
exposed that patients with no lymph node metastasis
and CTC negativity demonstrated increased sFlt1 values
in contrast to the reduced sFlt1 levels in patients with
no lymph node metastasis and CTC positivity. The
spearman correlation coefficient calculated the p-value
of 0.039 which was furthermore sustained by the Mann-
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Whitney-U-Test p = 0.041. ROC analysis assessed the
AUC value of 0.350 (see Fig. 3a).
Nonetheless, statistical analysis demonstrated no sig-
nificant correlation concerning patients without lymph
node involvement in respect to the vascular markers
PIGF, VEGF, VEGF-C and VEGF-D. Furthermore, pa-
tients with lymph node metastasis, with and without the
presence of CTCs, displayed no significant difference in
respect to the vascular markers sFlt1, PIGF, VEGF, VEGF-
C and VEGF-D.
Grading G2 vs. Grading G3
The collective graded G2 showed significant correlations
amongst patients with the presence or absence of CTCs
in terms of the vascular marker sFlt1. The box-plot ana-
lysis identified that patients graded with a G2 breast
cancer and furthermore being negative for CTCs display
higher levels of sFlt1 in comparison to the decreased
values of sFlt1 in G2 graded breast cancer with the
presence of CTCs. The spearman correlation coefficient
evaluated the p-value of 0.041 which was additionally
Fig. 1 a: Box plot analysis of sFLT1 expression in sera of breast cancer patients. We identified a significant enhanced sFLT1 release in CTC
negative patients compared to patients being CTC positive p = 0.034. In addition ROC analysis was performed. AUC value is 0.413. b: Box plot
analysis of PlGF expression in sera of breast cancer patients. We identified a significant enhanced PlGF values in CTC negative patients compared
to patients being CTC positive p = 0.043. In addition ROC analysis was performed. AUC value is 0.417
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sustained by the Mann-Whitney-U-Test p = 0.042. To
continue, ROC analysis was performed, revealing an
AUC value of 0.381 (see Fig. 4a). None of the other
vascular markers tested revealed differences in expres-
sion patterns in terms of Grading.
Hormone receptor type presence vs. absence
Furthermore, the statistical analysis also verified no sig-
nificant correlation regarding the presence or absence of
each single hormone receptor type; Progesterone recep-
tor, oestrogen receptor, Her2/neu, in patients with breast
cancer with and without the presence of CTCs, with re-
spect to the vascular markers sFlt1, PIGF, VEGF, VEGF-
C and VEGF-D.
Triple positive vs. triple negative
Moreover, no statistically significant correlation could be
demonstrated with the general comparison of a triple
negative hormone receptor to a triple positive breast
cancer with and without the presence of CTCs in terms
of the vascular markers sFlt1, PIGF, VEGF, VEGF-C and
VEGF-D.
Fig. 2 a: Box plot analysis of sFLT1 expression in sera of breast cancer patients who survived. We identified significant enhanced sFLT1 release in
the survived patient collective and patients being CTC negative p = 0.030. In addition ROC analysis was performed. AUC value is 0.401. b: Box plot
analysis of PlGF expression in sera of breast cancer patients who survived. We identified significant enhanced PlGF release in the survived patient
collective and patients being CTC negative p = 0.026. In addition ROC analysis was performed. AUC value is 0.398
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Vascular marker correlation
Significant correlation could be validated with the
spearman correlation coefficient for the association be-
tween the vascular markers itself. The vascular markers
examined were sFlt1, PIGF, VEGF, VEGF-C and VEGF-
D. In regard to the total patient collective, with and with-
out the presence of CTCs, significant correlations were
found between sFlt1 and PIGF (p = 0.000066), sFlt1 and
VEGF-C (p = 0.022), PIGF and VEGF (p = 0.038), VEGF
and VEGF-C (p = 0.045), VEGF-C and VEGF-D (p =
0.0000001) (see Fig. 5).
Discussion
Within this study we analysed the distribution of angio-
genic markers: sFlt1, PIGF, VEGF, VEGF-C and VEGF-D
and reveal the differences of their expression in the sera
of breast cancer patients with and without circulating
tumour cells. Significantly enhanced sFlt1 values were
Fig. 3 Box plot analysis of sFLT1 expression in sera of breast cancer patients with no lymph node metastasis. We identified significant enhanced
sFLT1 release in the patient collective with no lymph node involvement and CTC negativity p = 0.041. In addition ROC analysis was performed.
AUC value is 0.350
Fig. 4 Box plot analysis of sFLT1 expression in sera of breast cancer patients with a G2 graded tumour. We identified significant enhanced sFLT1
release in the G2 graded patient collective and CTC negativity p = 0.042. In addition ROC analysis was performed. AUC value is 0.381
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shown for the group of patients diagnosed with no
CTCs. It is implied that sFlt1, which is the extra-cellular
soluble domain of the VEGF receptor 1 (VEGFR1), traps
VEGF thus acting as an important factor in the negative
down regulation of angiogenesis [26, 27]. Furthermore,
sFlt1 is described as an inhibiting factor of the pro-
angiogenic VEGFR2 that acts as a positive signal con-
ductor, whereas VEGFR-1 is a suppressor of VEGFR-2 sig-
nalling, consequently decreasing the neo-vascularisation
stimulus [27, 28]. The tumour growth and the develop-
ment of an invasive, aggressive and metastatic breast can-
cer are essentially reliant on the neo-vascularisation to
provide blood supply for the nourishment and growth of
the tumour. One can consequently suggest that the in-
creased sFlt1 values in the CTC negative collective cause a
significant disruption of tumour vascularisation, inhibiting
CTCs being released into the peripheral blood. One could
also suggest a significant additive inhibition delay in
tumour growth, explaining and ensuing in the absence of
CTCs in those patients.
This hypothesis is furthermore supported by increased
levels of sFlt1 in the sera of the survived breast cancer
patient collective and no CTC involvement. The ability
of sFlt1 to bind and neutralize its target as it moves
through the interstitial matrix is mostly described for
one of the greatest powerful regulatory angiogenic agent
VEGF [29, 30]. The role of sFlt1 has been previously
shown to exercise a favourable outcome and advanced
therapeutic effect in several tumour models [31]. There-
fore, sFlt1 might have a major impact on anti-angiogenic
activity by the requisitioning and neutralization of
tumour secreted pro-angiogenic factors such as VEGF.
This angiogenic inhibition might therefore contribute to
slower and decreased tumour growth, inhibiting circula-
tion specific metastasis, thus enhancing survival and
resulting in a favourable conduct of those breast cancer
patients.
To continue, the group of patients with no lymph
node metastasis and no CTC involvement in the periph-
eral blood also indicated significantly enhanced sFlt1
expression. It is hypothesized that sFlt1 inhibits endo-
thelial cell proliferation and sprouting in the tumours
microenvironment, resulting in a decrease of the total num-
ber of tumour blood vessels, as well as the number of per-
fused vessels, demonstrating a combined anti-tumour and
anti-vascular effect [9, 28]. The tumours microenvironment
in association to sFlt1 values might therefore benefit from
its anti-angiogenic effects by successfully inhibiting lym-
phangiogenesis. One can consequently suggest that sFlt1
not only acts as an important factor in terms of down regu-
lating neo-vascularisation hence decreasing tumour pro-
gression, but also influences lymph metastasis formation in
favour of patient outcome.
Furthermore, in the sera of breast cancer patients
with a G2 histologically graded tumour and CTC nega-
tivity, showed significantly enhanced sFlt1 expression.
It is implicated that sFlt1 leads to a significant delay in
tumour growth without altering the revascularization of
ischemic peripheral tissue [26, 32]. Also, sFlt1 presum-
ably does not directly control growth of the malignant
tumour cells but is linked with a more favourable out-
come through the restriction of tumour vascularization
[33]. Therefore, significantly enhanced sFlt1 expressions
in CTC negative patients indicate a correlation with
medium differentiated (G2) breast cancer patients and
resulting in a favourable breast cancer manner.
Fig. 5 Spearman correlation of vascular markers: sFlt1, PIGF, VEGF, VEGF-C and VEGF-D. In regard to the total patient collective, significant correlation
was found between: sFlt1 and PIGF (p = 0.000066), sFlt1 and VEGF-C (p = 0.022), PIGF and VEGF (p = 0.038), VEGF and VEGF-C (p = 0.045) and VEGF-C
and VEGF-D (p = 0.0000001)
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Similarly to the sFlt1 values pattern, significantly en-
hanced Placental growth factor (PlGF) values were shown
for the group of patients diagnosed with no CTCs in con-
trast to CTC positive breast cancer patients. Furthermore,
increased levels of PlGF were also proven in the sera of
the survived breast cancer patient collective and no CTC
involvement. sFlt1 and PlGF values therefore correlate in
these patient collectives, both showing enhanced values.
PlGF also belongs to the VEGF family, which exclu-
sively binds to the sFlt1 receptor (VEGFR1) [34]. The
association between PlGF and sFlt1 has already been
established, especially in terms of preeclampsia. Placen-
tal production of sFlt1 is increased during preeclampsia
[35, 36], whereas PlGF and VEGF are decreased during
active disease and several weeks before commencement
of symptoms [37]. sFlt1 hereby acts as a potent anti-
angiogenic factor, binding and neutralizing the pro-
angiogenic proteins VEGF and PlGF, playing a key role
in the inhibition of placental angiogenesis [38]. Never-
theless, the role of PlGF in terms of tumour angiogenesis
and tumour growth remains controversial. Some studies
claim that PlGF promotes tumour angiogenesis and
tumour growth [39–41], although numerous other ana-
lyses indicated that overexpression of PlGF in tumour
cells suppresses tumour neovascularization and growth
[42–47]. Research implies that in addition to forming
homodimers, PlGF and VEGF can also form heterodi-
mers that contrary to prior evidence may be inactive and
function as inhibitors of tumour angiogenesis [11, 43,
48]. Therefore, PlGF may negatively modulate VEGF-
induced angiogenesis by formation of biologically in-
active heterodimers [43, 46, 49]. It is furthermore im-
plied that PlGF in tumours significantly normalizes
tumour vessels against vascular leakage, whereas block-
ing sFlt1 leads to an increased vascular leakage, thus
causing a less favourable outcome [47]. Our results in
terms of enhanced PlGF values in the CTC negative pa-
tient collective and furthermore in the survived breast
cancer patient collective and no CTC involvement sup-
ports the implication that tumour derived PlGF nega-
tively modulates tumour angiogenesis and tumour
growth [47]. This hypothesis if furthermore supported
by the increased levels of sFlt1 in these patient collec-
tives as it is presumed that PlGF stimulates the prolifera-
tion of cell types that express sFlt1 [50]. Therefore one
can suggest that the tumour derived PlGF in our breast
cancer patients suppresses tumour angiogenesis, tumour
growth and metastasis by a probable mechanism includ-
ing PlGF homodimers or PlGF–VEGF heterodimers, ac-
tivating a negative neovascularisation feedback via sFlt1
activation. Moreover, this hypothesis is reinforced by the
significant correlations amongst the vascular markers. Sig-
nificant correlation between sFlt1 and PlGF emphasize their
association as well as the significant correlation between
PlGF and VEGF, implying the presence of PlGF-VEGF
heterodimers.
These findings demonstrate the functional interaction
of sFlt1 and PlGF, suggesting that their overexpression
in tumour cells inhibits CTCs entering the peripheral
blood, thus emphasising a significant anti-angiogenic ef-
fect, inhibiting tumour growth and metastasis. Further-
more, in regard to CTC negativity, sFlt1 and PlGF values
may potentially serve as predictive markers.
Conclusion
Circulating tumour cells (CTCs) are a prognostic marker
for reduced disease free survival, breast cancer–specific
survival, and overall survival. CTC negative patients dis-
played increased sFlt1 expression opposed to CTC posi-
tive breast cancer patients. Furthermore, significant
enhanced PIGF values were also disclosed in CTC nega-
tive patients compared to patients being CTC positive.
In former studies, a functional interaction of sFlt1 and
PlGF was found. Results of our study suggest that their
overexpression in tumour cells inhibits CTCs entering
the peripheral blood. Furthermore, in regard to CTC
negativity, sFlt1 and PlGF values may potentially serve
as predictive markers.
Abbreviations
CTC, circulating tumour cells; sFlt1, soluble fms-like tyrosine kinase-1; PIGF,
phosphatidylinositol-glycan biosynthesis class F protein; VEGF, vascular
endothelial growth factor
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